He was the leader of the Translational Research and Bioengineering Group at HRI, a unit he established after completing postdoctoral studies in the Biodesign Innovation Program at Stanford University. His mission was to ‘translate’ scientific discoveries at the lab bench into exciting new treatments for cardiovascular disease. He is also an Interventional Cardiologist at the Royal Prince Alfred Hospital where he heads an internationally recognised team providing cutting-edge treatment of heart valve and coronary artery disease.